Dynavax Technologies reported $108.27M in Sales Revenues for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Abbvie ABBV:US $ 14342M 383M
Adma Biologics ADMA:US $ 20.68M 2.85M
Agenus AGEN:US $ 252.95M 242.22M
Alexion Pharmaceuticals ALXN:US $ 1636.5M 44.7M
Amgen AMGN:US $ 6706M 180M
Astrazeneca AZN:US $ 9866M 1646M
AstraZeneca AZN:LN 9866M 1646M
Biogen BIIB:US $ 2778.9M 3.9M
Biomarin Pharmaceutical BMRN:US $ 408.74M 92.95M
Bristol Myers Squibb BMY:US $ 11624M 79M
Chimerix CMRX:US $ 0.11M 0.28M
Dynavax Technologies DVAX:US $ 108.27M 55.5M
Gilead Sciences GILD:US $ 7421M 1204M
Glaxosmithkline GSK:US $ 9077M 985M
Gw Pharmaceuticals GWPH:US $ 152.47M 4.24M
Merk MRK:US $ 13154M 1752M
Minerva Neurosciences NERV:US $ 0 0
Nektar Therapeutics NKTR:US $ 24.92M 3.41M
Neurocrine Biosciences NBIX:US $ 296M 7.1M
Novartis NOVN:VX SF 13367M 73M
Pfizer PFE:US $ 24094M 5117M
Regeneron Pharmaceuticals REGN:US $ 3452.8M 1685.7M
Sarepta Therapeutics SRPT:US $ 189.41M 25.32M
Tg Therapeutics TGTX:US $ 2.03M 0.48M
Vertex Pharmaceuticals VRTX:US $ 1984.16M 190.79M